In an attempt to make Brazil less dependent on imported products and services, and at the same time promote its competitiveness and greater insertion in the global market, the Federal Government has launched in recent years a series of public policies as elements of incentives for innovation.
In the health area, for example, the government defends, as an innovation policy, the creation of a "Health Industrial Complex", with the conviction that its purchasing power, to supply the needs of the Unified Health System (SUS), is a determining factor for the success of this policy.
Among the routes or mechanisms to foster the construction of this "Health Industrial Complex", we have the "Basic Productive Process" (PPB), which establishes the government's purchase preference for products and services of national origin, even if they cost up to 25% more than imported ones. In this case, the company needs to prove to the competent Ministries its national content.
Another important mechanism is the Technological Compensation (CT), in which the company that wins a public bid assumes the commitment to install in Brazil, in a determined period of time, a production unit of the technological part that the government considers strategic.
Inova Saúde is another program in which the government made available in April 2012 resources of up to two billion reais for companies that want to invest in research and development (R&D) of health technologies considered as strategic for SUS. Among the areas covered by this program are in Vitro Diagnostics, Cardiology, Oncology, orthopedic implants, women's health, neurology, and diabetes, with a total of R$600 million.
Additionally, the government created in September 2013, the EMPRAPII - Brazilian Research and Innovation Company - which aims to create and coordinate a network of laboratories that can support those who propose to innovate. In the health area alone, 3.6 billion Reais have been made available for financing this process.
Finally, there is the "Productive Development Policy" (PDP), through which a national or foreign company decides to transfer a certain technology, elected as strategic by the Government, to a public laboratory. In this case, the Government commits to buy from this company, without public bidding, for the duration of such transfer. It is the legal form that the government found to become the owner of technologies considered strategic for SUS.
In conclusion, it is strategic for organizations to stay connected with the incentive mechanisms for innovation, because the opportunities lie precisely in the convergence between the needs indicated by the Government and the opportunities for organizations to collaborate in this process of transformation of the country's current technological environment. This process not only applies to the healthcare area, but in all others.